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Abstract
Breast cancer remains one of the leading causes of cancer-associated death worldwide. Conventional treatment is associ-
ated with substantial toxicity and suboptimal efficacy. We, therefore, developed and evaluated the in vitro efficacy of an 
autologous dendritic cell (DC) vaccine to treat breast cancer. We recruited 12 female patients with stage 1, 2, or 3 breast 
cancer and matured their DCs with autologous tumour-specific lysate, a toll-like receptor (TLR)-3 and 7/8 agonist, and an 
interferon-containing cocktail. The efficacy of the vaccine was evaluated by its ability to elicit a cytotoxic T-lymphocyte 
response to autologous breast cancer cells in vitro. Matured DCs (≥ 60% upregulation of CD80, CD86, CD83, and CCR7) 
produced high levels of the Th1 effector cytokine, IL12-p70 (1.2 ng/ml; p < 0.0001), compared to DCs pulsed with tumour 
lysate, or matured with an interferon-containing cocktail alone. We further showed that matured DCs enhance antigen-specific 
CD8 + T-cell responses to HER-2 (4.5%; p < 0.005) and MUC-1 (19%; p < 0.05) tetramers. The mature DCs could elicit a 
robust and dose-dependent antigen-specific cytotoxic T-lymphocyte response (65%) which was tumoricidal to autologous 
breast cancer cells in vitro compared to T-lymphocytes that were primed with autologous lysate loaded-DCs (p < 0.005). 
Lastly, we showed that the mature DCs post-cryopreservation maintained high viability, maintained their mature phenotype, 
and remained free of endotoxins or mycoplasma. We have developed a DC vaccine that is cytotoxic to autologous breast 
cancer cells in vitro. The tools and technology generated here will now be applied to a phase I/IIa clinical trial.
Keywords Dendritic cell vaccine · Immunotherapy · Breast cancer · Tumour lysate · Autologous primary breast cancer 
cells
Abbreviations
7-AAD  7-aminoactinomycin D
CD49f  Integrin alpha 6
CD40L  CD40 ligand
Ep-CAM  Epithelial cell adhesion molecule
ER  Estrogen receptor
MUC-1  Mucin-1
NK  Natural killer
Poly I:C  polyinosinic:polycytidylic acid
PR  Progesterone receptor
Th cell  T helper cell
Treg  Regulatory T cell
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0026 2-018-2238-5) contains 
supplementary material, which is available to authorized users.
 * Keertan Dheda 
 keertan.dheda@uct.ac.za
1 Division of Pulmonology and UCT Lung Institute, 
Department of Medicine, Centre for Lung Infection 
and Immunity, Groote Schuur Hospital, University of Cape 
Town, Old Main Building, H46.41, Groote Schuur Drive, 
Observatory, Cape Town 7925, South Africa
2 Department of General Surgery, University of Cape Town 
and Groote Schuur Hospital, Cape Town, South Africa
3 Division of Radiation Oncology, Department of Radiation 
Medicine, University of Cape Town and Groote Schuur 
Hospital, Cape Town, South Africa
4 National Health Laboratory Services (NHLS), Groote Schuur 
Hospital, Haematology, Cape Town, South Africa
5 Division of Haematology, University of Cape Town, 
Cape Town, South Africa
6 Institute of Infectious Diseases and Molecular Medicine, 
University of Cape Town, Cape Town, South Africa
72 Cancer Immunology, Immunotherapy (2019) 68:71–83
1 3
Introduction
Cancer remains one of the leading causes of death world-
wide with approximately 14 million new cases in 2012 and 
8.8 million related deaths recorded in 2015 [1]. Breast can-
cer represents 14% of the total global cancer-related deaths 
in females [2]. Breast cancer staging was defined accord-
ing to standard guidelines [3]. Stage 1 was defined as a 
tumour < 20 mm in size that was confined to one breast 
only. Stage 2 was defined as a tumour < 50 mm in size 
with or without malignant cell invasion of auxiliary lymph 
nodes and/or lymph nodes near the breastbone. Stage 3 
was defined as a tumour > 5 cm which had spread to auxil-
iary lymph nodes and/or lymph nodes near the breastbone 
or any size tumour that has spread to other areas within 
the breast. Stage 4 was defined as breast cancer that has 
metastasised beyond the breast to the lungs, lymph nodes, 
skin, bones, liver or brain.
Surgery for the most part is an effective treatment 
method, but its success is limited to the early stages of 
the disease before breast cancer has metastasised. Other 
forms of therapy, including chemotherapy, are partially 
effective but are associated with substantial and severe 
adverse events. Thus, new therapeutic options are urgently 
required.
DC are potent antigen presenting cells, which prime 
and activate T-cells during microbial or viral infection [4]. 
DCs offer an attractive immunotherapeutic option because 
they can be primed with different antigens in vitro to tar-
get different diseases in vivo. Various TLR agonists (e.g. 
TLR-3 [Ampligen® and Poly I:C] and TLR-7/8 [R848]) 
have been used to mature DCs in vitro for use as immuno-
therapeutic agents against malignant melanoma [5], pros-
tate cancer [6], malignant glioma [7] and renal cancer [6]. 
These DCs have the ability to express bioactive IL-12p70, 
IFN-α, IFN-γ, and TNF-α [8–10], indicating that they can 
support anti-tumour Th1 responses. By contrast, earlier 
DC vaccines could cross-present tumour antigens but 
lacked either co-stimulatory ability or lymph node homing 
capacity, or they produced low levels of IL12-p70, which 
is essential for Th1 polarising immunity [11]. The ability 
of DCs to produce IL-12p70 has been shown to directly 
translate to clinical benefits in vivo [12–14].
Over the last 5 years’ clinical trials have been conducted 
involving different cancers using different DC vaccines, 
which support the efficacy of DCs as immunotherapeutic 
agents [15–17]. Notably, these studies evaluated vaccines 
developed using cancer cell lines. However, in contradis-
tinction to cell lines there is considerable antigenic vari-
ability amongst tumours from different individuals with 
the same type of cancer. For example, the commonly used 
MCF-7 breast cancer cell line does not expresses some 
antigens that are highly expressed in 75–80% of breast 
cancers encountered in clinical practice [18–21]. This may 
result in poor vaccine efficacy because of tumour antigen 
heterogeneity [4, 16]. To address this issue, we tested DC 
vaccine efficacy to the patient’s own tumour cells in vitro 
(and to our knowledge the first study to do so) by recruit-
ing female patients with stage 1, 2 and 3 breast cancer.
We show that we can optimally mature patient-derived 
DCs in vitro with tumour-specific lysate, Ampligen®, an 
IFN-containing cocktail (IFN-α, IFN-γ, IL-1β, CD40L) and 
R848. We cultured and used patient-derived primary breast 
cancer cells as “targets” to test the efficacy of the DC vac-
cine in vitro. The mature DCs had the ability to prime effec-
tor cells, which resulted in Th1 cytotoxic CTL-mediated 
killing of the patient’s own breast cancer cells in vitro. We 
further show that the mature DCs were sterile, endotoxin/
mycoplasma free, and they maintained their mature phe-
notype and high viability 2 months’ post-cryopreservation.
Methods
Study site and population
Women undergoing surgery as the standard of care at Groote 
Schuur Hospital in Cape Town, South Africa were identi-
fied as potential participants. Patients over the age of 18 and 
diagnosed with stage 1, 2, or 3 breast cancer were recruited 
to the study and written informed consent was obtained. 
A clinical research form was completed for every patient 
recruited, which indicated age, reproductive status and 
medication status. Exclusion criteria included (i) patients 
undergoing immunotherapy, (ii) patients receiving immu-
nosuppressive medication (iii) patients on hormonal treat-
ment for breast cancer, (iii) active second malignancies, i.e. 
any malignancy not treated with curative intent within the 
last 5 years, (iv) patients with auto-immune disease, (v) any 
substance abuse. All participants agreed to donate a piece 
of malignant breast tissue and to undergo a leukapheresis 
procedure at a later date.
Autologous breast cancer cell culture
Approximately, ten 10 mm × 2 mm biopsy specimens (mean 
weight = 244 mg; Table 1) were obtained from the core of 
each tumour post-surgery (mean size = 22 mm × 21 mm [w 
× d]; Table 1) and the tissue was cut into 1 mm by 1 mm 
pieces and separated into two equal portions; for autolo-
gous breast cancer cell culture and for the generation of a 
tumour lysate. The autologous primary cells were isolated 
from the biopsy sample using Collagenase II according to 
the manufacturers specifications (Ambion, USA). The cells 
were washed and seeded in the appropriate culture vessel at 
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100% confluency in DMEM/F12 medium containing 10% 
human A/B serum (Western Province Blood Transfusion 
Services, South Africa), 100 IU penicillin/streptomycin, 
0.1 mM sodium pyruvate (Lonza, Switzerland), 10 µg/ml 
insulin, 10 µg/ml transferrin, 10 µM ethanolamine, 10 ng/ml 
selenium (DMEM/F12-10; Sigma–Aldrich, Germany) and 
100 nM estradiol (Sigma–Aldrich, Germany). After 2 days 
incubation at 37 °C the medium was replaced without estra-
diol, but with 100 nM cortisol (Sigma–Aldrich, Germany) 
to prevent fibroblast growth [22, 23]. The cells were continu-
ally cultured until 100% confluency. They were lifted with 
trypsin/EDTA (Lonza, Switzerland) and cultured in larger 
culture vessels until the cells were confluent (~ 2 ×  107 cells 
in total) in a T175 tissue culture flask (Greiner, Germany). 
The cells were cultured in DMEM/F12-10 without cortisol 
one week prior to co-culture with the effector T-cells. We 
demonstrated that we had the ability to culture the primary 
breast cancer cells for several weeks. Each culture was cryo-
preserved in DMEM/F12 with 40% human A/B serum and 
10% DMSO as indicated below.
Preparation of tumour lysate
For the generation of a tumour lysate, the tumour tissue was 
homogenised on ice with a tissue ruptor (Qiagen, Germany). 
The homogenate was subjected to 5 freeze thaw cycles, 
which involved snap freezing in liquid nitrogen followed by 
incubation at 37 °C for 5 min. Total protein was determined 
using a standard Bradford assay (BioRad, USA) as per the 
manufacturer’s instruction.
Culture conditions to obtain mature DCs
Each patient underwent a leukapheresis procedure using 
the Colbe Spectra Optia® Apheresis System (Terumo BCT, 
USA). Following leukapheresis the monocytes (~ 2 ×  107 
cells) were purified by plastic adherence and differentiated 
into immature DCs with CellGenix DC medium (CellGe-
nix, Germany) containing 100 µg/mL IL-4 and GM-CSF 
(Prospec Bio, Israel) for 5 days at 37 °C. After 5 days, 
immature DCs were pulsed with or without 100 µg/ml of 
tumour-specific lysate for 6 h at 37 °C and then matured 
with or without or with different combinations of 100 µg/mL 
Ampligen® (Hemispherx Biopharma, USA), an IFN-con-
taining cocktail (25 ng/mL IFN-γ, 10 ng/mL IFN-α, 10 ng/
mL IL1-β, 1 µg/mL CD40L; Prospec Bio, Israel) and 2.5 µg/
mL R848 (InvivoGen, USA) for 42 h at 37 °C. Supernatants 
derived from the mature DCs were stored at − 80 °C for 
IL12-p70 analysis by the ELISA.
Phenotypic assessment of the mature DCs using 
flow cytometry
Immature and mature DCs were stained with HLA-DR 
PerCP/Cy5.5, CD40 FITC, CCR7 PE, CD80 PE/CY7, CD86 
PE-Dazzle 594 and CD83 APC (Biolegend, USA). The cells 
were acquired using a LSRII flow cytometer (Beckton Dick-
inson, USA) and analysed using FloJo software (version 
10.1; Treestar, USA). Dead cells were gated out of the scat-
ter plots prior to analysis and negative gates were set using 
mean fluorescence one (MFO) controls.
Table 1  Demographic data of the cohorts used in study and phenotypic characterisation of the primary breast cancer cells
IHC immunohistochemistry, FC flow cytometry, HLA human leukocyte antigen, + denotes 0–25% expression, ++ denotes 25–50% expression, 
+++ denotes 50–75% expression, ++++ denotes 75–100% expression, IC inconclusive. ND not determined
Patient ID Age Race Stage Tumour size
(w×d) [mm]
Tumour 
biopsy weight 
(mg)
Invasive Antigens 
expressed (IHC)
Detected (Yes/
No)
Antigens expressed (FC) HLA-type
ER PR HER-2 Ep-CAM CD49f MUC-1 HER-2
PC001 44 African 3 21×20 253 Yes No Yes Yes + +++ +++ +++ A30, A68
PC003 58 Mixed 2 25×20 404 No No No IC ++ + +++ ++++ A02, A30
PC004 71 Mixed 3 20×15 186 No No Yes Yes +++ ++++ +++ ++++ A30, A33
PC007 58 Mixed 3 20×15 220 No No Yes Yes ++ +++ +++ ++++ A03, A11
PC009 39 Mixed 2 20×15 345 No Yes Yes Yes + ++ +++ ++++ A01, A03
PC010 44 Mixed 2 30×30 192 No Yes Yes Yes + + +++ ++++ A02, A66
PC011 42 Mixed 1 20×20 116 No Yes Yes Yes ++ + +++ ++++ A02, A24
PC012 48 Mixed 2 35×30 224 No Yes Yes Yes ND ND ND ND A02, A11
PC013 41 African 3 40×45 165 Yes No No Yes +++ ++ +++ ++++ A02
PC015 38 Mixed 2 11×12 216 Yes No No Yes +++ ++ +++ ++++ A02, A03
PC016 44 Mixed 3 7×16 185 Yes Yes Yes Yes +++ ++ +++ ++++ A02, A26
PC021 41 Mixed 3 20×16 320 No Yes Yes Yes +++ +++ ++++ ++++ A02, A24
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Confocal microscopy
Monocytes, immature DCs and mature DCs were prepared 
as indicated previously. The cells were allowed to adhere 
to 3-aminopropyltriethoxysilane (APES; Sigma, Germany) 
coated slides overnight at 37 °C. The next day the cells 
were stained with or without or in combination with CD14 
PE/Cy7, CD40 FITC and or CD83 APC (Becton Dickin-
son, USA) and the slides were mounted in Mowiol (Calbi-
ochem, USA) containing n-propyl gallate (Sigma–Aldrich, 
Germany) as anti-fading agent. Confocal microscopy was 
performed with a Zeiss Axiovert 200M LSM 510 Meta 
NLO Confocal Microscope using the 40X water immer-
sion objective and the 63X oil-immersion objective.
Cytospin, haematoxylin, eosin staining and light 
microscopy
Monocytes, immature DCs and mature DCs were con-
centrated onto glass slides using cytospin (Cytospin 3, 
Shandon, UK) and stained with haematoxylin and eosin 
(Merck, Germany) using a standard technique. The slides 
were viewed using a Nikon light microscope with the 100x 
oil-immersion objective.
Immunohistochemistry of the breast cancer 
biopsies
Immunohistochemistry of the biopsy samples using anti-
bodies directed to the estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 
(HER-2) were performed by the National Health Labora-
tory Services (NHLS) at Groote Schuur Hospital, Cape 
Town, South Africa.
Phenotypic characterisation of the autologous 
breast cancer cells using flow cytometry
The autologous breast cancer cells were stained with 
HER-2 PE, epithelial cell adhesion molecule (Ep-CAM) 
PE-Dazzle 594, mucin-1 (MUC-1) PE-Cy7 and integrin 
alpha 6 (CD49f) APC (Biolegend, USA) as recommended 
by the manufacturer. The cells were acquired on the LSRII 
flow cytometer and the data were analysed as indicated 
previously.
IL12‑p70 ELISA
The expression of IL12-p70 was determined using a 
standard ELISA technique from the culture supernatants 
obtained above according to the manufacturer’s specifica-
tions (Mabtech, Sweden).
Generation of effector cells
Mature DCs prepared as previously described, were co-cul-
tured with PBMCs as described by Koido et al. [24]. Briefly, 
mature DCs were co-cultured with PBMCs at a ratio of 1:10 
in RPMI (Lonza, Switzerland) medium supplemented with 
10% human A/B serum (Western Province Blood Transfu-
sion Services, South Africa), 2 mM L-glutamine, 25 mM 
HEPES, 0.1 mg/mL sodium pyruvate, 100 IU/ml penicil-
lin and 100 mg/ml streptomycin (R-10; Sigma, Germany). 
After 3 days of culture the medium was replaced with fresh 
medium containing 10 U/ml IL-2 (Roche, Switzerland). The 
cells were then cultured for an additional 4 days at 37 °C to 
generate the effector cells.
Determination of cytotoxicity and CTL–induced cell 
death of autologous breast cancer cells
The autologous breast cancer cells were washed then 
detached with Accumax (Innovative Cell technologies, 
USA) as indicated by the manufacturer. The autologous 
breast cancer cells were then co-cultured with the effector 
cells (generated as indicated) at various ratios of 2:1, 5:1 
and 10:1 (effector cells : autologous breast cancer cells). 
Autologous cells alone served as a negative control. After 
4 h of incubation at 37 °C, cytotoxicity was determined 
using the LDH assay (Cytotoxicity Detection  KitPlus LDH; 
Roche, Germany) and cell death was measured using 7-ami-
noactinomycin D (7-AAD; Becton Dickinson, USA) by flow 
cytometry.
Tetramer assay
The MHC-1-specific tetramers used in the current study 
were HLA-02 positive, therefore, only matched patient 
samples were analysed for the recognition of HER-2 and 
MUC-1 antigens by the TCRs of CD8 + T-cells. Effector 
cells were stained with MUC-1 PE tetramer, HER-2 APC 
tetramer (MBL, USA), CD8 FITC (Becton Dickinson, USA) 
and Zombie NIR (Biolegend, USA) as recommended by the 
manufacturer then acquired by flow cytometry and analysed 
as previously indicated.
Cryopreservation, sterility and endotoxin/
mycoplasma determination
Mature DCs were cryopreserved in R-10 containing 10% 
DMSO (Sigma, Germany) and 40% human A/B serum at 
a concentration of 1 ×  107/ml at − 80 °C. After 2 months’ 
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cryopreservation, the viability was assessed using trypan 
blue staining and the maturation phenotype by flow 
cytometry.
Routine bacterial and mycological sterility testing was 
conducted on every batch of mature DCs by the NHLS at 
Groote Schuur Hospital, Cape Town, South Africa. The lev-
els of endotoxin and mycoplasma was determined using the 
Endpoint Chromogenic Limulus Amoebocyte Lysate (LAL) 
Assay (ThermoFisher, Scientific, USA) or the MycoAlert™ 
detection kit (Lonza, Germany) according to the manufac-
turer’s specifications, respectively.
Statistics
Data were analysed for statistical significance by one-way 
Anova with Dunnets post-test or a Wilcoxon signed rank 
paired t test using GraphPad Prism software (version 6.0; 
GraphPad Software, USA), where *, **, ***, **** indicate 
p < 0.05, p < 0.01, p < 0.005, p < 0.0001, respectively.
Results
Patients and samples
Two hundred and twenty-four female patients with stage 1, 
2 and 3 breast cancer were asked to consent to the study 
(Fig. 1). Thirty-two patients declined and 171 did not meet 
the inclusion criteria. Of the remaining 21 a further 7 with-
drew and 2 were excluded; one failed to disclose her hor-
monal treatment and the other did not have enough biopsy 
material to complete the assays. The remaining 12 female 
patients were included in the preclinical study.
The demographics of the study cohorts are shown in 
Table 1. The median age of the patients was 47 years. The 
mean size of the tumours and weight of the biopsy speci-
mens were 22  mm × 21  mm and 244  mg, respectively 
(Table 1). The patients were more likely to have non-inva-
sive stage 3 breast cancer and the tumours expressed dif-
ferent breast cancer antigens including, the ER and PR as 
determined by immunohistochemistry (IHC; Table 1). All 
the tumours were HER-2 positive. The autologous breast 
cancer cells all expressed high levels of MUC-1/HER-2 and 
variable levels of the epithelial (Ep-CAM) and epithelial 
progenitor (CD49f) markers as determined by flow cytom-
etry (Table 1). Each patient was HLA typed to match them 
to the HER-2 and MUC-1 tetramers (HLA-A02) used in the 
study. All the patients had normal blood counts prior to leu-
kapheresis (data not shown).
DCs from breast cancer patients pulsed 
with tumour‑specific lysate and matured with 
Ampligen®, an IFN‑containing cocktail and R848 
or IFN‑containing cocktail alone express high levels 
of key co‑stimulatory molecules
In optimisation experiments we showed that Ampligen®, 
an IFN-containing cocktail (IFN-α, IFN-γ, CD40L and 
IL-1β) and R848, resulted in optimal maturation of the 
DCs as assessed by the upregulation of HLA-DR, CD40, 
CD80, CD86, CCR7 and CD83 (data not shown). We 
also further showed that these mature DCs produced high 
Fig. 1  Patient recruitment plan for the DC vaccine breast cancer 
preclinical trial. Two hundred and twenty-four patients were asked 
to consent to the study. Two hundred and three patients were not 
included in the study because they either declined or they did not 
meet the inclusion criteria. Of the remaining 21 patients who con-
sented to the study a further 9 were excluded or withdrew from the 
trial. In total 12 patients were included in the current preclinical trial
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levels of the Th1 effector cytokine, IL12-p70 (6 ng/1×106/
ml; data not shown). The monocytes, immature DCs and 
mature DCs were morphologically distinct from one 
another (Fig. 2a). The immature and mature DCs were 
larger than the monocytes and dendrites were clearly vis-
ible on the surface of the cells.
Approximately, a mean of 1 ×  109 PBMCs were 
obtained by leukapheresis for each patient. The PBMCs 
were washed and monocytes were isolated by plastic 
adherence. After differentiation into immature DCs using 
IL-4 and GM-CSF, the cells were pulsed with or without 
100 µg/mL tumour-specific lysate for 6 h at 37 °C. The 
cells were then matured with or without, an IFN-contain-
ing cocktail (10 ng/mL IFN-α, 25 ng/mL IFN-γ, 1 µg/mL 
CD40L and 10 ng/mL IL-1ß), 100 µg/mL Ampligen® and/
or 2.5 µg/mL R848 for 42 h at 37 °C. The maturation phe-
notype was determined by flow cytometry (Fig. 2b). From 
this point forward IFN-containing cocktail, Ampligen® 
and R848 will be referred to as full cocktail.
The DCs that were matured with an IFN-containing 
cocktail only or pulsed with tumour-specific lysate and 
matured with full cocktail, expressed significantly higher 
levels of CD40 (p < 0.001 or p < 0.005, respectively) and 
HLA-DR (p < 0.005) compared to immature DC (data not 
shown). More importantly, the DCs pulsed with tumour-
specific lysate then matured with full cocktail or IFN-
containing cocktail alone, expressed significantly higher 
levels of the key maturation markers, CD80 (69% or 73%, 
respectively; p < 0.005), CD86 (78% or 81%, respectively; 
p < 0.0001), CCR7 (62% or 64%, respectively; p < 0.0001) 
and CD83 (73% or 75%, respectively; p < 0.0001), com-
pared to the immature DCs (39% vs 5% vs 27% vs 1.7%, 
respectively) or DCs pulsed with tumour-specific lysate 
alone (56% vs 15% vs 42% vs 8%, respectively; Fig. 2B).
Mature DCs from breast cancer patients produce 
high levels of the Th1 effector cytokine, IL‑12p70
The ability of mature DCs to produce biologically active IL-
12p70 is a direct indicator of how clinically effective a DC 
vaccine can be because it has the ability to activate effector T 
cells in vivo, that have the potential to drive an anti-tumour 
response [25–27]. For this reason, we determined the rela-
tive expression levels of IL12-p70 from the culture superna-
tants of the mature DCs using an IL-12p70 ELISA (Fig. 3).
The immature DCs or DCs pulsed with tumour-specific 
lysate only produced no detectable levels of IL-12p70 
(Fig. 3). In contrast, DCs pulsed with tumour-specific lysate 
and matured with full cocktail expressed high levels of IL-
12p70 (1.21 ng/1×106/ml, SD = 0.3–3.7; Fig. 3; p < 0.0001). 
When the cells were matured with IFN-containing cocktail 
only the levels of IL-12p70 (0.6 ng/1×106/ml) were signifi-
cantly different (two-fold less) to the cells that were pulsed 
with tumour-specific lysate and matured with full cocktail 
(p < 0.005). This highlights the significant role of Ampli-
gen® and R848 as maturation agents which favour a Th-1 
response.
The TCRs of CD8 + T‑cells primed 
with tumour‑specific lysate and full 
cocktail‑matured DCs can detect HER‑2 and MUC‑1 
antigens on MHC‑1 specific tetramers
The MHC-1-specific tetramers were HLA-02 positive 
hence, it was only possible to analyse patients with the 
HLA-02 phenotype. The effector cells were stained with 
the MUC-1 and HER-2 tetramers as indicated in the meth-
ods. Both HER-2 (4.5%; p < 0.005) and MUC-1 (19%; 
p < 0.05) tetramers detected the TCRs on CD8 + T-cells 
that were primed with the tumour-specific lysate and full 
cocktail-matured DCs (Fig. 4). A 1.3- and 1.9-fold decrease 
in HER-2 (3%; p < 0.05) and MUC-1 (11%) antigen recogni-
tion was observed by the TCRs of the CD8 + T cells primed 
with DCs matured in the absence of tumour-specific lysate, 
respectively.
Cytotoxic‑T‑cell mediated killing of autologous 
breast cancer cells with tumour‑specific lysate 
and full cocktail‑matured DC primed effector cells
Next, we wanted to determine if the mature DC-primed 
effector cells could elicit a CTL response, which was tumori-
cidal to autologous breast cancer cells in vitro. Effector cells 
Fig. 2  DCs from patients with breast cancer, pulsed with tumour-
specific lysate and matured with Ampligen®, an IFN-containing 
cocktail and R848 and or with IFN-containing cocktail only express 
higher levels of co-stimulatory molecules compared to immature DCs 
or DCs pulsed with tumour-specific lysate only. Immature DCs were 
differentiated from monocytes, incubated in CellGenix DC complete 
medium with or without 100 µg/mL tumour-specific lysate for 6 h at 
37 °C. The cells were then matured with or without or in combination 
with 100  μg/ml  Ampligen®, an IFN-containing cocktail (10  ng/mL 
IFN-α, 25 ng/mL IFN-γ, 1 µg/mL CD40L and 10 ng/mL IL-1β), and/
or 2.5 µg/mL R848 for 42 h at 37 °C. The monocytes, immature DCs 
and mature DCs were subjected to a haematoxylin and eosin stain 
(a) or were stained with CD14 PE-CY7 (monocytes), CD40 FITC 
(immature and mature DCs) and or CD83 APC (mature DCs; A) for 
confocal microscopy. The maturation phenotype was also determined 
by flow cytometry (b). Arrows (→) show dendrites being expressed 
on the surface of mature DCs. Data were analysed for statistical sig-
nificance by one-way Anova with Dunnett’s post-test, where **, *** 
and **** indicate p < 0.01, p < 0.005 and p < 0.0001, respectively. 
Each of the treatments were compared to the control group (iDCs). 
Error bars represent standard deviation. Light microscopy magnifica-
tion: ×100 (oil immersion); scale bars = 20 µm. Confocal magnifica-
tion: ×63 (oil immersion); scale bars = 10 µm. iDCs = immature DCs
◂
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generated as previously described were co-cultured with the 
autologous breast cancer cells for 4 h. Cytotoxicity of the 
autologous breast cancer cells was determined using an LDH 
assay (Fig. 5a, b). In addition, cell death of the autologous 
breast cancer cells was measured by flow cytometry using 
7-AAD (Fig. 5c, d).
When the effector cells were primed with tumour-spe-
cific lysate and full cocktail-matured DCs, the median lev-
els of autologous breast cancer cell cytotoxicity were 65% 
(Fig. 5a). In contrast levels of cytotoxicity were 11%, 13% 
and 15%, when the effector remained un-primed or were 
primed with tumour-specific lysate or IFN-containing cock-
tail only-matured DCs, respectively. We also showed that the 
levels of cytotoxicity observed were dose-dependent when 
the effector cells were primed with tumour-specific lysate 
and full cocktail-matured DCs (Fig. 5b). Once again, the 
cytotoxic response confirms the importance of Ampligen® 
and R848 as maturation agents.
Having shown that the effector cells which were primed 
with tumour-specific lysate, and full cocktail-matured DCs 
could elicit a cytotoxic response to the autologous breast 
cancer cells in vitro, we wanted to determine if these cells 
were tumoricidal in vitro. A two-fold increase (p < 0.05) in 
cytotoxic-mediated autologous breast cancer cell kill was 
observed with effector cells that were primed with tumour-
specific lysate and full cocktail-matured DCs compared to 
autologous cells not cultured with effector cells (Fig. 5c). 
We also observed a dose-dependent increase in autologous 
breast cancer cell kill when the effector cells were primed 
with tumour-specific lysate and full cocktail-matured DCs 
(Fig. 5d).
The tumour‑specific lysate and full cocktail‑matured 
DCs were sterile, endotoxin/mycoplasma free 
and cryopreservation does not affect their 
maturation phenotype or viability
For the proposed phase I/IIa clinical trial, the vaccine will 
be administered over a 2-month period. For this reason, we 
wanted to determine if 2 months of cryopreservation affects 
the maturation phenotype or viability of the DCs. As shown 
in Table S1, cryopreservation had no effect on the matura-
tion phenotype of the DCs or on the viability of these cells. 
The expression levels of the co-stimulatory markers, CD80, 
CD86, CCR7 and CD83 remained at 84%, 86%, 68% and 
77%, respectively. The mean viability was 74% and we show 
that all the vaccine preparations were sterile and endotoxin/
mycoplasma free.
Discussion
We have developed a Th1-polarising DC vaccine that has 
high efficacy against patient-derived breast cancer cells 
in vitro. We show that we can optimally mature DCs in vitro 
with autologous tumour-specific lysate and a cocktail con-
taining cytokines and TLR agonists. The mature DCs pro-
duced high levels of the Th1 effector cytokine IL12-p70. In 
addition, the TCRs of the mature DC-primed CD8 + T-cells 
could recognise HER-2 and MUC-1 antigens using a 
tetramer assay. We further show that these mature DCs could 
prime effector cells, which resulted in cytotoxic killing of 
patient-specific autologous breast cancer cells in vitro. To 
our knowledge this is the first DC vaccine preclinical cancer 
study that has tested the efficacy of the vaccine against the 
patient’s own tumour cells in vitro. This is critical to meas-
ure vaccine efficacy as breast cancer antigen heterogeneity is 
high relative to that in cancer cell lines [18, 19, 21].
A major finding was that the IL-12p70-producing mature 
DCs were proficient in co-stimulating CD8 + antigen-spe-
cific tumoricidal responses. This was only observed when 
Ampligen® and R848 were included during maturation 
together with tumour-specific lysate and the IFN-containing 
Fig. 3  DCs pulsed with tumour-specific lysate and matured with 
Ampligen®, an IFN-containing cocktail and R848 express higher lev-
els of the Th1 effector cytokines, IL-12p70, compared to the imma-
ture DCs (iDCs) or DCs pulsed with tumour-specific lysate only. The 
level of IL-12p70 from the culture supernatants of the immature DCs 
or matured DCs was determined using the ELIZAPRO IL-12p70 
detection kit from Mabtech as indicated by the manufacturer. Data 
were analysed for statistical significance by one-way Anova with 
Dunnett’s post-test or Wilcoxon signed rank paired t test, *, ***, **** 
indicate p < 0.05, p < 0.005 and p < 0.0001, respectively. For Anova 
each of the treatments were compared to the control group (iDCs). 
Error bars represent standard deviation
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cocktail. Although the use of DCs as an adoptive cell-
mediated therapy for cancer has been widely used [28], our 
study differs considerably from others as we used autolo-
gous breast cancer cells as “target” cells in vitro (and to our 
knowledge the first to do so). The levels of toxicity reported 
here are comparable to other studies where the investigators 
utilised cell lines to test vaccine efficacy [10, 12, 29]. How-
ever, the precise levels of cell line-specific cytotoxicity are 
difficult to measure because of tissue mismatch and induc-
tion of an allogenic immune response occurring in tandem, 
thus underestimating the incremental efficacy of our vaccine. 
For example the commonly used MCF-7 cell line express 
very low to undetectable levels of HER-2 [21]. In contrast 
HER-2 is expressed in some breast cancers that present at the 
clinic [18, 19]. Therefore, vaccines directed to cell lines may 
not truly represent the antigenic phenotype of autologous 
tumours. In this study, all the tumour cells expressed high 
levels of HER-2, which further highlights the limitations of 
using cell lines as a model system to test vaccine efficacy.
We showed that the DCs which were pulsed with tumour-
specific lysate and matured with full cocktail expressed high 
levels of CCR7. The high expression levels of co-stimula-
tory molecules together with CCR7 expression indicate that 
the DCs not only have optimal T- and natural killer (NK) 
cell co-stimulatory capacity [30] but also optimal lymph 
node homing ability [31]. The infiltration of DCs into pri-
mary tumour lesions has been associated with significantly 
prolonged patient survival [32]. A meta-analysis of clinical 
trials involving DC-based immunotherapy favoured admin-
istration of vaccines closest to lymph nodes [6] as only 4–5% 
of the DCs reach the draining lymph nodes [33]. CCR7 is 
the dominant receptor involved in the migration of DCs to 
the draining lymph node, and thus the upregulation of the 
homing cytokine, CCR7, in our study further supports the 
use of our DC vaccine as a candidate for therapy.
The individual components included to induce maturation 
in the current study were chosen to favour type-1 polarisa-
tion. Both IFN-γ and CD40L drive high levels of IL-12p70 
expression [34] and IL-12p70 and IFN-γ are important for 
CD8 + T-cell memory development [27]. The TLR ago-
nists, Ampligen® and R848 have been shown to enhance 
the expression of IFN-γ and IL-12p70 from DCs [9, 35]. 
Interestingly, R848 induces myeloid-derived suppressor cell 
(MDSC) differentiation into macrophages and DCs [36]. It 
is thus an attractive candidate for enhancing the effects of 
cancer immunotherapy as cells differentiated from MDSCs 
by the action of R848 exert higher proliferation-inducing 
activity on antigen-primed T cells compared to untreated 
MDSCs [36].
We initially pulsed the immature DCs with a tumour 
lysate prepared from biopsies of breast cancer patients. A 
meta-analysis from 3444 cancer patients has shown that 
patients treated with tumour lysate-matured DCs have 
a more favourable outcome than patients treated with 
Fig. 4  The TCRs of CD8 + T-cells primed with tumour-specific 
lysate/Ampligen®/IFN-cocktail and R848-matured DCs can rec-
ognise HER-2 and MUC-1-specific tetramers. Immature DCs were 
differentiated from monocytes as indicated previously. DCs were 
matured and effector cells were generated as indicated in the meth-
ods. The cells were stained with CD8 FITC, CD3 PerCP/Cy5.5, 
HER-2 APC, MUC-1 PE and Zombie NIR according to the manufac-
turer’s instructions (MBL, USA). The levels of HER-2 and MUC-1 
recognised by the TCR on CD8 + T-cells were determined by flow 
cytometry. Data were analysed for statistical significance by one-way 
Anova with Dunnett’s post-test where *, *** indicate p < 0.05 and 
p < 0.005, respectively. Each of the treatments were compared to the 
control group (T-cells primed with IFN-cocktail matured DCs not 
stained with HER-2/MUC-1 tetramer). Error bars represent standard 
deviation
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Fig. 5  PBMCs from breast cancer patients co-cultured with tumour-
specific lysate pulsed and Ampligen®/IFN-containing cocktail/R848-
matured DCs results in cytotoxic T-lymphocyte-mediated killing of 
primary breast cancer cells in vitro. Matured DCs were prepared as 
indicated in the methods. The matured DCs were then co-cultured 
with PBMC at a ratio of 1:10 for 7 days at 37 °C. The primary breast 
cancer cells were incubated with or without the primed PBMCs 
(effector cells) at a ratio of 1:10 (a and c) or the primary cells were 
incubated with the effector T-cells at various ratios indicated (b and 
d) for 4 h at 37 °C. Cytotoxicity (a and b) was determined using the 
LDH assay (Cytotoxicity Detection  KitPlus LDH; Roche, Germany) 
and cell death (c and d) of the primary breast cancer cells was meas-
ured by flow cytometry. Data were analysed for statistical significance 
by one-way Anova with Dunnett’s post-test where *, ***indicate 
p < 0.05 and p < 0.005, respectively. Each of the treatments were com-
pared to the control group (primary breast cancer cells incubated in 
the absence of PBMCs). Error bars represent standard deviation
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peptide-matured DCs [37]. Electroporation of patient-spe-
cific tumour mRNA has been reported to be a more efficient 
method to enhance MHC class I-mediated antitumor immu-
nity, which mediates a cytotoxic T-cell response without 
functional deterioration of the DCs [38]. However, in our 
extensive optimisation studies we found that electroporation 
of the DCs resulted in suboptimal viability and decreased 
co-stimulatory molecule expression on the mature DCs (data 
not shown).
We show that the tumour-specific lysate and full cock-
tail-matured DCs produced high levels (1.2 ng/1×106/ml/
ml) of IL12-p70. A number of human in vitro DC vaccine 
preclinical trials indicate that IL-12p70 expression is an 
important predictor of how effective a vaccine can be in 
an in vivo clinical setting [12, 13] and IL-12p70 has been 
shown to be indispensable in regulating T-cell effector func-
tion [39–42] and NK-induced antitumor responses [43]. In 
addition mature DCs that produce high levels of IL-12p70 
have increased antigen presentation capacity [39] as well as 
an increased capacity to induce CTL responses to tumour 
cells [44].
There are limitations to the current study. It was only 
conducted at one site, so the efficacy of the vaccine was 
not tested in different clinical settings. However, this was 
an in vitro preclinical trial and not a phase II or III clinical 
study. The flow cytometry cell death data may not repre-
sent a true reflection of the actual levels of cell lysis and/
or death over the 4-h incubation period. The CTL assay is 
more representative of actual cytotoxicity levels because the 
assay measures cell membrane lysis over the entire incu-
bation period, while flow cytometry would only measure 
whole intact dead cells. As a result, the flow cytometric 
assay would not measure cells that have already lysed or 
are in the process of lysing due to cytotoxicity. Finally, we 
were unable to recruit patients with stage 4 breast cancer. 
However, the immunomodulatory capacity of stage 3 and 4 
breast cancer patients would be expected to be similar.
In conclusion, we have developed a DC vaccine to breast 
cancer, which had potent Th1 polarising ability that is 
tumoricidal to autologous breast cancer cells in vitro. This 
has not been reported before and the techniques and meth-
odology used in this preclinical trial will be applied in a 
phase I safety study.
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